Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation

Conditions

Atrial Fibrillation

Keywords

Stroke, Embolism, Atrial fibrillation

Brief summary

This is an international observational study in patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism.

Paulus Kirchhof, Sylvia Haas, Pierre Amarenco, Alexander G.G. Turpie, Miriam Bach et al. (8 authors)

EP Europace2024-06-266 citations

10.1093/europace/euae183

Impact of gender: Rivaroxaban for patients with atrial fibrillation in the <scp>XANTUS</scp> real‐world prospective study

A. John Camm, Pierre Amarenco, Sylvia Haas, Miriam Bach, Paulus Kirchhof et al. (9 authors)

Clinical Cardiology2020-09-084 citations

10.1002/clc.23452

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban.

Kirchhof P, Haas S, Amarenco P, Hess S, Lambelet M, van Eickels M, Turpie AGG, Camm AJ, XANTUS Investigators*.

2020-02-2120 citations

10.1161/jaha.118.009530

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER).

Beyer-Westendorf J, Camm AJ, Fox KAA, Le Heuzey JY, Haas S, Turpie AGG, Virdone S, Kakkar AK, RIVER Registry Investigators.

2019-04-258 citations

10.1186/s12959-019-0195-7

Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis.

de Jong LA, Gout-Zwart JJ, van den Bosch M, Koops M, Postma MJ.

2019-01-1510 citations

10.1080/13696998.2018.1563404

Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study

Pierre Amarenco, Sylvia Haas, Susanne Hess, Paulus Kirchhof, Marc Lambelet et al. (8 authors)

European Heart Journal - Cardiovascular Pharmacotherapy2018-11-1233 citations

10.1093/ehjcvp/pvy041

Global Prospective Safety Analysis of Rivaroxaban

Paulus Kirchhof, Ghazi Radaideh, Young‐Hoon Kim, Fernando Laņas, Sylvia Haas et al. (11 authors)

Journal of the American College of Cardiology2018-07-0165 citations

10.1016/j.jacc.2018.04.058

Design and baseline characteristics of the Xarelto Post‐Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (<scp>XAPASS</scp>)

Satoshi Ogawa, Kazuo Minematsu, Takanori Ikeda, Takanari Kitazono, Jyoji Nakagawara et al. (12 authors)

Journal of Arrhythmia2018-02-0716 citations

10.1002/joa3.12034

Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study

A. John Camm, Alexander G.G. Turpie, Susanne Hess, Pierre Amarenco, Marc Lambelet et al. (9 authors)

EP Europace2017-07-0715 citations

10.1093/europace/eux127

XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation

A. John Camm, Pierre Amarenco, Sylvia Haas, Susanne Hess, Paulus Kirchhof et al. (8 authors)

European Heart Journal2015-09-01447 citations

10.1093/eurheartj/ehv466

Interventions

DRUGRivaroxaban (Xarelto, BAY59-7939)

Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* Female and male patients ≥ 18 years of age with a diagnosis of non-valvular atrial fibrillation who start treatment with rivaroxaban to prevent stroke or non-CNS (Central Nervous System) systemic embolism, and who consent to participate in the study

Design outcomes

Primary

Measure	Time frame
Adjudicated major bleeding events	after 1 year or until 30 days after end of rivaroxaban therapy
Safety variables will be summarized using descriptive statistics based on adverse events collection	after 1 year or until 30 days after end of rivaroxaban therapy

Secondary

Measure	Time frame
All cause mortality	after 1 year or until 30 days after end of rivaroxaban therapy
Adjudicated symptomatic thromboembolic events	after 1 year or until 30 days after end of rivaroxaban therapy
Persistence with rivaroxaban treatment: Reasons for any switch from or interruption of rivaroxaban treatment	after 1 year or until 30 days after end of rivaroxaban therapy

Countries

Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Hungary, Ireland, Israel, Moldova, Netherlands, Norway, Poland, Portugal, Russia, Slovakia, Slovenia, Sweden, Ukraine, United Kingdom

Outcome results

None listed